Anvisa's five-strong board voted unanimously not to approve the Russian vaccine after technical staff had highlighted"inherent risks" and"serious" defects, citing a lack of information guaranteeing its safety, quality and effectiveness.
A crucial issue was the presence in the vaccine of the adenovirus that could reproduce, a"serious" defect, according to Anvisa's medicines and biological products manager Gustavo Mendes. But, like Anvisa, the European Union has not yet approved the vaccine, saying it needs more information on the tests and manufacturing process.
So what happened to BRICS arrangement 🤷🏿♀️
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.